Successful Tocilizumab Treatment for Scleritis.
Ocul Immunol Inflamm
; 28(2): 285-287, 2020.
Article
en En
| MEDLINE
| ID: mdl-31411511
Purpose: To present a rare case of scleritis associated with a prior diagnosis of giant cell arteritis (GCA) that was unresponsive to glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, and azathioprine, but reached and maintained a full remission with tocilizumab.Observations: A 62-year-old Caucasian female presented with scleritis and headache. Four years earlier, the patient was diagnosed with GCA. Treatment with topical and systemic NSAIDs, prednisone and diverse disease-modifying antirheumatic drugsonly had a partial effect on the scleritis whilst the arthralgia and headaches increased. Despite the absence of laboratory evidence of active GCA, tocilizumab was started and the scleritis and headaches disappeared within several days. Prednisone could be fully tapered within 3 months and to date, 12 months after the start of tocilizumab, the patient has maintained a sustained remission.Conclusions: Our patient demonstrates that tocilizumab might represent a therapeutic option for scleritis, and its further evaluation for this severe ocular disease is worthwhile.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inducción de Remisión
/
Escleritis
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Diagnostic_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Ocul Immunol Inflamm
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Países Bajos
Pais de publicación:
Reino Unido